Erenumab in highly therapy-refractory migraine patients: First German real-world evidence.
Adult
Antibodies, Monoclonal, Humanized
/ therapeutic use
Calcitonin Gene-Related Peptide
/ therapeutic use
Calcitonin Gene-Related Peptide Receptor Antagonists
/ therapeutic use
Double-Blind Method
Female
Germany
Headache
/ drug therapy
Headache Disorders, Secondary
Humans
Male
Middle Aged
Migraine Disorders
/ drug therapy
Receptors, Calcitonin Gene-Related Peptide
Retrospective Studies
1. migraine
2. erenumab
3. therapy
4. real-world
5. CGRP antibody
Journal
The journal of headache and pain
ISSN: 1129-2377
Titre abrégé: J Headache Pain
Pays: England
ID NLM: 100940562
Informations de publication
Date de publication:
03 Jul 2020
03 Jul 2020
Historique:
received:
26
03
2020
accepted:
18
06
2020
entrez:
5
7
2020
pubmed:
6
7
2020
medline:
18
11
2020
Statut:
epublish
Résumé
Calcitonin gene related peptide (CGRP) monoclonal antibodies (mAB) are the first specific migraine prophylactic medication. Erenumab is the only CGRP mAB targeting the CGRP receptor. Clinical data regarding efficacy and tolerability of erenumab in highly therapy-refractory patients are not available, yet, although many patients treated with CGRP mAB under real world conditions can be considered as highly therapy-refractory. Clinical routine data of highly therapy-refractory migraine patients treated with erenumab 70 mg for 3 months between November 2018 and December 2019 in the West German Headache Center, University Hospital Essen, Germany, were analysed. Monthly migraine days (MMD), monthly headache days (MHD) and days of acute medication intake (AMD) were assessed. Statistical analysis was performed using the Wilcoxon test. Descriptive statistics were performed to evaluate changes of vegetative symptoms, acute medication response, side effects, as well as treatment satisfaction. Complete clinical data were available for 26 episodic (EM) and 74 chronic (CM) migraineurs. Sixty-six % (n = 49) of CM patients had an additional medication overuse headache (MOH). After 3 months 57.7% of EM patients and 41.9% of CM patients had a 50% or greater reduction of MMD. The mean number of MMD was reduced by 3.43 (SE 1.26) in EM, and by 4.72 (SE 0.87) in CM. Thirty-nine patients (52.7%) returned from chronic to episodic course of migraine. After 3 months, 23 patients (46.9%) were not suffering from a MOH anymore. Erenumab seems to be a promising therapeutic option in highly therapy-refractory migraine patients. Retrospective registered.
Sections du résumé
BACKGROUND
BACKGROUND
Calcitonin gene related peptide (CGRP) monoclonal antibodies (mAB) are the first specific migraine prophylactic medication. Erenumab is the only CGRP mAB targeting the CGRP receptor. Clinical data regarding efficacy and tolerability of erenumab in highly therapy-refractory patients are not available, yet, although many patients treated with CGRP mAB under real world conditions can be considered as highly therapy-refractory.
METHODS
METHODS
Clinical routine data of highly therapy-refractory migraine patients treated with erenumab 70 mg for 3 months between November 2018 and December 2019 in the West German Headache Center, University Hospital Essen, Germany, were analysed. Monthly migraine days (MMD), monthly headache days (MHD) and days of acute medication intake (AMD) were assessed. Statistical analysis was performed using the Wilcoxon test. Descriptive statistics were performed to evaluate changes of vegetative symptoms, acute medication response, side effects, as well as treatment satisfaction.
RESULTS
RESULTS
Complete clinical data were available for 26 episodic (EM) and 74 chronic (CM) migraineurs. Sixty-six % (n = 49) of CM patients had an additional medication overuse headache (MOH). After 3 months 57.7% of EM patients and 41.9% of CM patients had a 50% or greater reduction of MMD. The mean number of MMD was reduced by 3.43 (SE 1.26) in EM, and by 4.72 (SE 0.87) in CM. Thirty-nine patients (52.7%) returned from chronic to episodic course of migraine. After 3 months, 23 patients (46.9%) were not suffering from a MOH anymore.
CONCLUSIONS
CONCLUSIONS
Erenumab seems to be a promising therapeutic option in highly therapy-refractory migraine patients.
TRIAL REGISTRATION
BACKGROUND
Retrospective registered.
Identifiants
pubmed: 32620151
doi: 10.1186/s10194-020-01151-0
pii: 10.1186/s10194-020-01151-0
pmc: PMC7333436
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Calcitonin Gene-Related Peptide Receptor Antagonists
0
Receptors, Calcitonin Gene-Related Peptide
0
erenumab
I5I8VB78VT
Calcitonin Gene-Related Peptide
JHB2QIZ69Z
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
84Références
Neurol Sci. 2019 May;40(Suppl 1):177-179
pubmed: 30927136
J Headache Pain. 2019 Oct 30;20(1):99
pubmed: 31666008
Neurol Clin. 2019 Nov;37(4):651-671
pubmed: 31563225
J Headache Pain. 2019 Jan 16;20(1):6
pubmed: 30651064
Lancet Neurol. 2017 Jun;16(6):425-434
pubmed: 28460892
Neurology. 2019 May 14;92(20):e2309-e2320
pubmed: 30996056
Cephalalgia. 1988;8 Suppl 7:1-96
pubmed: 3048700
Cephalalgia. 2018 May;38(6):1026-1037
pubmed: 29471679
Lancet Neurol. 2019 May;18(5):459-480
pubmed: 30879893
J Headache Pain. 2020 Apr 7;21(1):32
pubmed: 32264820
Lancet. 2019 Sep 21;394(10203):1030-1040
pubmed: 31427046
N Engl J Med. 2017 Nov 30;377(22):2123-2132
pubmed: 29171821
Lancet. 2018 Nov 24;392(10161):2280-2287
pubmed: 30360965